Euronext Green Planet France NR (GRF5N) News

Know Labs to Present at the American Diabetes Association’s Scientific Sessions

Latest clinical research results demonstrate a stable MARD in an expanded dataset. Know Labs, Inc. (NYSE American: KNW), a leading developer of...

Form S-1 - General form for registration of securities under the Securities Act of 1933

Know Labs Joins the Industrial Participant Program of the Wyss Institute for Biologically Inspired Engineering at Harvard University

The Company’s experience in developing novel, next generation medical diagnostic technology aligns with the Wyss Diagnostics Accelerator’s...

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Know Labs Appoints Chris Somogyi as President, International

Somogyi to lead Know Labs’ “Skunkworks” Program and drive global revenues. Know Labs, Inc. (NYSE American: KNW), an emerging leader in...

Know Labs, Inc. Reports Second Quarter FY 2024 Results

Know Labs, Inc. (NYSE American: KNW), a leading developer of non-invasive medical diagnostic technology, today reported financial results for the...

Know Labs to Present Clinical Research at the 2024 American Association of Clinical Endocrinology Annual Meeting

The Company’s oral abstract presentation features results from its clinical study that demonstrate the accuracy and medical application of its...

Know Labs, Inc. to Host Review of Second Quarter Fiscal Year 2024 Results on May 15, 2024

Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it will host a webcast...

Know Labs to Present Clinical Research at the 2024 American Physiology Summit

The Company demonstrates significant progress since presenting at last year’s Summit. Know Labs, Inc. (NYSE American: KNW), an emerging developer...

Form 8-K/A - Current report: [Amend]

Form 8-K - Current report

Know Labs’ Non-Invasive Glucose Monitor Achieves 11.1% MARD in Latest Clinical Research Study

Know Labs’ first study including participants with diabetes and venous blood as a comparative reference demonstrates its proprietary sensor’s...

Form 8-K - Current report

Know Labs Secures U.S. $12 Million Funding for Company’s Further Execution on Its Clinical Research and Development Initiatives

Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it has entered into a...